Vimentin Is a Dominant Target of In Situ Humoral Immunity in Human Lupus Tubulointerstitial Nephritis

Objective In lupus nephritis (LN), severe tubulointerstitial inflammation (TII) predicts progression to renal failure. Severe TII is associated with tertiary lymphoid neogenesis and in situ antigen‐driven clonal B cell selection. The autoantigen(s) driving in situ B cell selection in TII are not kno...

Full description

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.) Vol. 66; no. 12; pp. 3359 - 3370
Main Authors Kinloch, Andrew J., Chang, Anthony, Ko, Kichul, Henry Dunand, Carole J., Henderson, Scott, Maienschein‐Cline, Mark, Kaverina, Natalya, Rovin, Brad H., Salgado Ferrer, Marlene, Wolfgeher, Don, Liarski, Vladimir, Haddon, D. James, Utz, Paul J., Wilson, Patrick C., Clark, Marcus R.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.12.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective In lupus nephritis (LN), severe tubulointerstitial inflammation (TII) predicts progression to renal failure. Severe TII is associated with tertiary lymphoid neogenesis and in situ antigen‐driven clonal B cell selection. The autoantigen(s) driving in situ B cell selection in TII are not known. This study was undertaken to identify the dominant driving autoantigen(s). Methods Single CD38+ or Ki‐67+ B cells were laser captured from 7 biopsy specimens that were diagnostic for LN. Eighteen clonally expanded immunoglobulin heavy‐ and light‐chain variable region pairs were cloned and expressed as monoclonal antibodies. Seven more antibodies were cloned from flow‐sorted CD38+ cells from an eighth biopsy specimen. Antigen characterization was performed using a combination of confocal microscopy, enzyme‐linked immunosorbent assay, screening protoarrays, immunoprecipitation, and mass spectrometry. Serum IgG titers to the dominant antigen in 48 LN and 35 non‐nephritic lupus samples were determined using purified antigen‐coated arrays. Autoantigen expression on normal and LN kidney was localized by immunohistochemistry and immunofluorescence. Results Eleven of 25 antibodies reacted with cytoplasmic structures, 4 reacted with nuclei, and none reacted with double‐stranded DNA. Vimentin was the only autoantigen identified by both mass spectrometry and protoarray. Ten of the 11 anticytoplasmic TII antibodies directly bound vimentin. Vimentin was highly expressed by tubulointerstitial inflammatory cells, and the TII antibodies tested preferentially bound inflamed tubulointerstitium. Finally, high titers of serum antivimentin antibodies were associated with severe TII (P = 0.0001). Conclusion Vimentin, an antigenic feature of inflammation, is a dominant autoantigen targeted in situ in LN TII. This adaptive autoimmune response likely feeds forward to worsen TII and renal damage.
Bibliography:Dr. Haddon is recipient of a Canadian Institutes for Health Research Fellowship.
Dr. Rovin has received consulting fees, speaking fees, and/or honoraria from Biogen Idec, Bristol‐Myers Squibb, Lilly, AstraZeneca, and Celtic Pharma (less than $10,000 each) and from GlaxoSmithKline (more than $10,000).
Drs. Kinloch and Clark have submitted a patent application pertaining to the use of antivimentin antibodies in the diagnosis of tubulointerstitial nephritis.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2326-5191
2326-5205
DOI:10.1002/art.38888